Modalities that act through different mechanisms can often provide synergistic antitumor activity for the treatment of refractory tumors when used in combination. Here we report a gene therapy approach in which the genes for the angiogenesis inhibitor, endostatin, and the marker protein and potent immunogen, green fluorescent protein ( GFP ) , were delivered to murine neuroblastoma cells prior to inoculation of the tumor cells into syngeneic immunocompetent mice. Although the effect of either angiogenesis inhibition or immunomodulation alone resulted in only a modest delay in tumor growth, when these approaches were used in combination, prevention of the formation of appreciable tumors was effected in 15 of 24 ( 63% ) mice. The combination of endostatin and GFP expression elicited a strong immune response that was T cell ± mediated and was reactive against both GFP and tumor cell line ± specific antigens. This afforded treated mice protection against subsequent tumor challenge with unmodified tumor cells. These results suggest that antiangiogenic and immunotherapy strategies, when used in a gene therapy ± mediated approach, can act synergistically in an effective multimodality anticancer approach. Cancer Gene Therapy ( 2001 ) 8, 537 ± 545
Endostatin has been shown to inhibit endothelial cell proliferation and migration in vitro, at least in part, through its ability to induce endothelial cell apoptosis. 8 In addition, it has been shown to be among the most potent inhibitors of tumor-induced angiogenesis in vivo and, consequently, to inhibit tumor growth in a variety of different murine models.
7,9 ± 11 Antiangiogenic therapy can even reduce an existing tumor burden by limiting the necessary blood supply. However, tumors may remain dormant but viable with this cytostatic treatment approach and may resume unregulated growth once the limitations of angiogenesis inhibition are removed. 11, 12 Therefore, long -term expression of an angiogenesis inhibitor such as endostatin is likely to be required for the successful treatment of cancer.
An alternative to chronic angiogenesis inhibition would be to combine this approach with a cytotoxic modality. Immunotherapy may be one such complementary tumoricidal approach. It has been used successfully in preclinical models for the eradication of minimal residual disease with long -term antitumor immune surveillance resulting in chronic tumor suppression. 13 ± 15 However, rarely does it induce rejection of large tumors. The generation of an antitumor immune response has often been successfully established through a gene therapy ±mediated approach in which tumor cells are modified to express foreign antigens that elicit a strong immune response. 16, 17 Immunity to unmodified (parental ) tumor cells may be established through``crosspriming'' to tumor-specific antigens. One potential immunogenic foreign antigen is the jellyfish green fluorescent protein (GFP ). This commonly used reporter molecule has been shown to be immunogenic in murine tumor models, inducing a classic T cell ± mediated cytotoxic response. 18 In this set of experiments, murine neuroblastoma cells were modified, using a retroviral vector, to express both endostatin for local angiogenesis inhibition, together with GFP, which has the potential for immune stimulation. Growth of these gene -modified tumor cells was then observed both in vitro and in vivo. These two complementary approaches, acting through different mechanisms, effected a synergistic anticancer response when used in combination in a murine model of neuroblastoma.
MATERIALS AND METHODS

Cell lines
The murine neuroblastoma cell line NXS2, provided by Dr. R. Reisfeld (La Jolla, CA ) , was maintained in RPMI-1640 medium (Bio -Whittaker, Walkersville, MD ) supplemented with 10% fetal bovine serum ( Bio -Whittaker ) , 100 units / mL penicillin ± 100 g /mL streptomycin (Gibco BRL, Grand Island, NY ) and 2 mM L -glutamine ( Gibco BRL ) . NXS2 was derived by hybridizing the C1300 murine (A /J strain ) neuroblastoma -derived cell line with murine dorsal root ganglion cells from C57BL / 6J mice and selecting for high dopamine and GD -2 expression. 19 This clone has been shown to have major histocompatibility class I antigen expression of the A /J mice, i.e., H2K k -positive /H2K bnegative. 19 293T cells 20 were maintained in Dulbecco's modified Eagle's medium ( DMEM; Bio -Whittaker ) with the same supplements as in the growth medium for NXS2. Human umbilical vein endothelial cells (HUVECs ) were obtained from Clonetics ( Walkersville, MD ) and were maintained in endothelial growth medium ( EGM ) .
Antibodies
Recombinant endostatin was generated from Escherichia coli as described by Boehm et al 11 using a bacterial expression plasmid for the murine protein obtained from Dr. J. Folkman (Boston, MA ). Goat polyclonal antiserum to murine endostatin was then raised (Panigen, Blanchardville, WI ). Three monthly injections of 1 mg of the recombinant protein, the first of which was in Freund's complete adjuvant while the latter were in incomplete adjuvant, were administered by subcutaneous injection to a goat. The serum subsequently harvested has demonstrated reactivity with murine endostatin in Western blot analysis.
Cloning and expression of mouse endostatin
The cDNA for mouse endostatin corresponding to the Cterminal 184 amino acids of mouse collagen XVIII was isolated by polymerase chain reaction amplification of cDNA from mouse liver, a site known to express high levels of collagen XVIII. The 5 H primer ( 5 H -TGCTCATACTCAT-CAGGACTTTCAGCC -3 H ) spanned the sequence encoding the N -terminal amino acids of endostatin, whereas the 3 H primer spanned the termination codon (5 H -AGCTGGCA-GAGGCCTATTTGGAGAAAG -3 H ). The amplified polymerase chain reaction products were then cloned into pCR2.1 ( Invitrogen, Carlsbad, CA ) and the insert was sequenced.
A signal peptide was then added to ensure that the endostatin would be secreted. Mouse collagen XVIII has been shown to have two potential signal peptides. 21 Peptide 1 is MAERWHLLDVLTSLVLLLVARVSWA -EP and peptide 2 is MAPDPSRRLCLLL -LLLLSCRL -VP. Two amino acids following the signal peptide cleavage site ( EP for signal peptide 1 and VP for signal peptide 2 ) were included in order to ensure that efficient cleavage would occur. In addition, a six -histidine tag was incorporated immediately 3 H to the signal peptide in order to facilitate detection and purification. Both the six -histidine tag and a signal peptide were added to the 5 H end of the endostatin cDNA using a complimentary oligonucleotide approach requiring two steps. Before the addition of oligonucleotides, the amplified endostatin was cloned into pSL1180 (Pharmacia, Piscataway, NJ ) by ligating the 625 -bp SpeI±EcoRV fragment from pCR2.1 -Endo into pSL1180 cut with NheI and EcoRV to give 80 -3 H Endo. For the endostatin containing signal peptide 1, the oligonucleotides ( shown below ) were annealed and ligated into 80-3 H Endo cut with PflMI and MluI:
The resulting plasmid, 80 -3 H EndoSP1, was then digested with XhoI and MluI, and the second set of oligonucleotides ( shown below ) was annealed and ligated to the digested plasmids:
The resultant plasmid was termed 80 -EndoSP1. For the endostatin containing signal peptide 2, the oligonucleotides ( shown below ) were annealed and ligated into 80 -3 H Endo, which had been cut with NarI and PflMI to give 80 -3 H EndoSP2:
The DNA encoding the 5 H end of signal peptide 2 was then inserted into 80 -3 H EndoSP2 by ligating the annealed oligonucleotides ( shown below ) to the 1.6 -kb NarI±NspV fragment from 80-3 H EndoSP2 and the 3.1 -kb XhoI±NspV fragment from pSL1180: WI ) digested with XhoI and ClaI to give 73 -EndoSP1 and 73 -EndoSP2, respectively. In order to make CMVEndoSP1 -pA, two separate ligation steps were required. First, the BamHI ± EcoRV fragment from pAVs6, 22 which contains the SV40 polyadenylation site, was ligated to 80 -EndoSP1 digested with EcoRV and BamHI to give 80 -EndoSP1 -pA. Then the CMV promoter from pCEP4 ( Invitrogen ) was cloned 5
H to 80 -EndoSP1 -pA using a three -way ligation among the BstBI ±XhoI fragment from pSL1180 ( the backbone of the plasmid ), the BstBI ±PmaCI fragment from 80 -EndoSP1 -pA (contains the EndoSP1 cDNA and SV40 polyadenylation site ) , and the SalI±PvuII fragment from pCEP4 (contains the CMV promoter ). CMVEndoSP2 -pA was then made by replacing the XhoI±EcoRV fragment from CMV-EndoSP1 -pA, which contains the EndoSP1 cDNA, with the XhoI±EcoRV fragment from 80 -EndoSP2, which contains the EndoSP2 cDNA.
Transcription / translation / translocation assay
Evaluation of in vitro transcription, translation, and translocation was performed using the TNT T7 coupled reticulocyte lysate system kit according to Promega Technical Bulletin 126. Endo1 and Endo2 proteins were synthesized in the presence of [
35 S] methionine (1200 Ci /mmol; Amersham, Piscataway, NJ ) in the absence or in the presence of canine pancreatic microsomal membranes (Promega) according to the manufacturer's instructions. After 90 minutes, the proteins were resolved on SDS polyacrylamide gel under reducing conditions and visualized by fluorography using the Amplify reagent ( Amersham ).
Retroviral vector construction
MSCV-Endo, a retroviral vector containing the endostatin expression cassette, was made by ligating the 741-bp XhoI± MunI fragment from 80 -EndoSP1 into MSCV-X, a MSCVbased vector that contains part of the polylinker from pSL1180, digested with XhoI and MunI. MSCV-Endo -I -GFP was made by ligating the 1463 -bp SpeI±BsaBI fragment from MSCV-Endo into MSCV-I-GFP (M ) 23 cut with SpeI and StuI. In these constructs, the expression of the endostatin cassette, containing the signal peptide and six -His tag, is under the control of the MSCV LTR (long terminal repeat ) , and in the latter vector, the GFP is linked to an internal ribosome entry site from encephalomyocarditis virus 3 H of the endostatin cDNA. 24 An additional retroviral vector was constructed in which the penultimate amino acid of the endostatin protein being expressed was proline rather than serine, as occurs in the wild -type protein. This was done in an attempt to create a more stable endostatin protein that might be resistant to carboxypeptidase hydrolysis. 25 This MSCV-Endo (P ) -I -GFP vector was made by cloning a 715 -bp SphI (site within the Endostatin cDNA ) ±ClaI (site 3 H to the Endostatin cDNA ) fragment into pSL1180 to give 80-3 H Endo. The mutation (serine to proline) was then introduced by annealing the two complimentary oligonucleotides shown below and ligating the annealed product into 80 -3 H Endo, which had been partially digested with XmnI ( site within the Endostatin cDNA ) and BamHI (site 3 H to the Endostatin cDNA ) to give 80-3 H Endo (P ):
The 3 H end of this mutated Endostatin was used to replace the 3 H end of the Endostatin within the MSCV-Endo -I -GFP by ligating the 237-bp SapI±BamHI fragment from 80 -3 H Endo( P) into MSCV-Endo -I -GFP, which had been partially digested with SapI and then to completion with BamHI.
Tumor cell line transduction NXS2 tumor cells were transduced with conditioned medium containing high -titer, VSV-G ( vesicular stomatitis virus ) ± pseudotyped MSCV-Endo, MSCV-Endo -I -GFP, MSCV-Endo (P ) -I -GFP, or MSCV-I-GFP vector particles, supplemented with 6 g/ mL polybrene. These conditioned media were derived by cotransfection of 293T cells with the respective retroviral vector plasmids and two helper plasmids, one containing the gag and pol retroviral genes and the other containing the gene for the VSV-G envelope, as described previously. 26, 27 GFP -expressing transduced cells were then sorted based on GFP expression by FACS ( Becton -Dickinson, Bedford, MA ) to recover highly transduced cells. These subpopulations were then expanded, with GFP expression being confirmed by FACS and endostatin expression being confirmed by western and ELISA (R&D Systems, Minneapolis, MN ).
Inhibition of HUVEC migration
Migration assays were performed in 6.5-mm tissue culture ± treated transwell plates ( Costar, Corning, NY ) . Eight-micron polycarbonate membranes were placed over a bottom chamber containing 2% gelatin that had been allowed to settle at room temperature for 30 minutes. Excess gelatin was then aspirated and replaced with an equal volume of DMEM + 0.1% BSA and incubated for 1 hour at 378C. Excess DMEM was aspirated from the bottom wells and replaced with EGM supplemented with VEGF (10 ng /mL; R&D Systems ) along with either endostatin or the proline -mutant endostatin (10 ng/ mL ) , or an equal volume of PBS. HUVECs (passage 5 ) were trypsinized and resuspended at 1Â10 6 cells / mL. The 5Â10 4 HUVECs were then added to each well in the upper chamber after preincubating the cells with either endostatin or the proline-mutant endostatin (10 ng/ mL ) for 30 minutes at 378C. Endostatin and the proline-mutant endostatin were purified from NXS2-Endo -I -GFP and NXS2 -Endo( P ) -I -GFP conditioned media using Ni 2 + ±NTA beads as described (QiaExpressionist Handbook; Qiagen, Santa Clarita, CA ) . The plates were then incubated for 6 hours at 378C with 5% CO 2 to allow the cells to migrate. Nonmigrated cells on the upper surface of the filter were removed by wiping with a cotton swab. The cells were then fixed with 10% formalin, stained with Harris' hematoxylin,
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Murine tumor models
Tumors were established in either syngeneic, immunocompetent A /J mice (Jackson Laboratory, Bar Harbor, ME ) or C.B -17 SCID (Charles River Laboratory, Wilmington, MA ) by subcutaneous injection of 2Â10 6 cells in 200 L PBS. Tumor measurements were performed in two dimensions with calipers twice weekly and volumes calculated as width 2 ÂlengthÂ0.5.
Cytotoxicity assays
Spleens were harvested from mice that had been challenged with either NXS2, NXS2-Endo -I -GFP, or NXS2-I-GFP cells. These spleens were then minced into single cell suspensions in PBS plus 2% fetal calf serum. Splenocytes were resuspended in ammonium chloride for 5 minutes at room temperature, after which they were washed and again resuspended in PBS plus serum. Splenocytes were then cocultured for 6 days with irradiated tumor cells, either NXS2 -Endo -I-GFP or NXS2 -I-GFP. Following this coculture, the splenocytes were recovered and incubated with 51 Cr-labelled, unmodified NXS2, NXS2-Endo -I -GFP, or NXS2 -I -GFP target cells at effector:target ratios of 40:1, 20:1, 10:1, and 5:1 in a V-bottomed microtiter plate ( Costar ) . One set of reactions was performed in the presence of anti -CD3 antibody (145 -2c11, H -2 kb ) from PharMingen, San Diego, CA. After 4 hours of incubation at 378C, the supernatant was harvested and radioactive release was measured. Maximal release of the incorporated chromium was determined by detergent lysis of the neuroblastoma cells. Percent -specific cytotoxicity was determined from the formula: % Specific cytotoxicity = [ ( Experimental release À Spontaneous release) / ( Maximum release À Spontaneous release) Â100 ].
T -cell depletion
Mice were depleted of T lymphocytes with anti -CD4 ( Gk1.5 ) and anti -CD8 (2.43 ) monoclonal antibodies 28, 29 kindly provided by Dr. P. Doherty (Memphis, TN ) . The antibody -containing ascites were diluted 1:5 and 1:10, respectively, in PBS. Five hundred microliters of either antibody was administered by intraperitoneal injection 4 days prior to tumor cell challenge and then every other day for the duration of the experiment. After tumor-bearing mice were sacrificed, successful depletion of approximately 99% of T cells was confirmed by FACS analysis of splenocytes ( not shown) .
Statistical analysis
Results are reported as means S.E.M. for tumor volumes. A Student's t test was used to analyze statistical differences among groups in the HUVEC migration assays and between tumor growth curves. A P value less than .05 was considered to be statistically significant.
RESULTS
Endostatin processing
The ability of the two potential signal peptides to be cleaved at the membrane was first tested by translating in vitro± transcribed RNA in the presence of canine microsomes. The results shown in Figure 1A indicate that the EndoSP1 construct was efficiently cleaved by the microsomes, resulting in a smaller polypeptide. The radioactive polypeptides both in the presence and absence of microsomes for EndoSP1 are of the expected molecular weight. On the other hand, the EndoSP2 construct was not cleaved. The minor bands in both lanes are due to translational starts at internal methionine.
This inability of signal peptide 2 to be cleaved in vitro is also consistent with the results obtained when 293T cells were transiently transfected with CMV-EndoSP1 -pA and CMV-EndoSP2 -pA (Fig 1B ) . Supernatants from the cell cultures were analysed by Western blot analysis with a goat polyclonal antisera. Endostatin was found to be present in the supernatant from 293T cells transfected with CMVEndoSP1 -pA, but not CMV-EndoSP2-pA, suggesting that signal peptide 2 is not functioning as a signal peptide. Therefore, signal peptide 1 was used in all of the remaining endostatin constructs. The recombinant endostatin shown in Figure 1B was synthesized in E. coli and serves as a control. It has eight more amino acids at the N -terminus than the endostatin from the transfected 293T cells and is, therefore, slightly larger. 6 cells /24 hours. These levels of endostatin expression by the transduced tumor cells in vitro were noted to be stable following continuous passage of cells for greater than 3 months (data not shown ); no silencing of the promoter in the tumor cells or selection for nontransduced cells was observed. NXS2 cells were also transduced with the MSCV-I-GFP. FACS sorting for high levels of GFP expression was performed to select for cells with high degrees of transduction in this cell line also. Following sorting, each of these three transduced cell lines had similar mean levels of GFP expression (Fig 2 ) with >99% of the cells in each of the lines expressing GFP.
The ability of the endostatin protein being expressed to inhibit HUVEC migration in response to VEGF was evaluated to test the functional activity of the protein in vitro. This has proven to be the most reproducible assay for us and others 30 when assessing endostatin function. Wild -type and mutant endostatin were purified from genemodified neuroblastoma -conditioned medium. The wildtype endostatin caused an 80% inhibition of VEGF -induced endothelial cell migration (P < .02) , whereas the mutant form of endostatin resulted in only a small and not statistically significant (P < .33) inhibition in this assay ( Fig 3 ) .
The doubling time for neuroblastoma cells expressing endostatin plus GFP was compared to that for GFP alone ( Fig 4 ) . Although endostatin purified from the genemodified tumor cells had a profound effect on endothelial cell migration in vitro, there was no effect on the intrinsic growth rate of the endostatin-expressing tumor cells in vitro.
Tumor growth in mice
The effect of autocrine expression of endostatin on in vivo tumor cell growth was evaluated by comparing the growth of NXS2 -Endo -I-GFP tumor cells with NXS2 -I-GFP tumor cells and unmodified NXS2 cells. The initial experiments were performed in SCID mice that are deficient of B and T lymphocytes in order to exclude any possible effect of anti -GFP immunity. The growth curves for the unmodified and GFP -expressing cells were identical (Fig 5A ) . The Endo -I -GFP ±expressing cells grew at a marginally slower rate than either control and gave rise to tumors that were smaller by 25% than controls after 27 days.
These experiments were then performed in syngeneic, immunocompetent A /J mice. The growth curves are shown in Figure 5B . Although there was now a slight difference observed in the growth rate of the unmodified tumor cells compared to those engineered to express GFP alone, it was not statistically significant. In addition, growth of other cells with higher GFP expression [ e.g., NXS2 -Endo( P ) -I-GFP ] was not slowed, suggesting that there was no effect of expression of the weakly immunogenic GFP protein on tumor growth. The NXS2 -Endo -I -GFP tumor cell growth was significantly restricted, however, compared to the growth of either of the other cell lines. In fact, 15 of 24 ( 63% ) mice failed to develop any evidence of a tumor either by palpation or histologic examination ( data not shown) . These mice were followed for a minimum of 3 months without the subsequent development of a tumor. Tumors that did grow from NXS2-Endo -I -GFP cells had a significant delay in the initiation of appreciable tumor growth compared to that observed for the unmodified tumor cells. These tumors were not derived from nontransduced clones as they were shown to express GFP by histologic examination and endostatin by ELISA (data not shown) .
Additional experiments were then performed in which NXS2 cells modified to express the mutant, nonfunctional endostatin plus GFP were inoculated into A /J mice. The growth of these tumor cells was not significantly different from that observed previously with the GFP -expressing tumor cells ( Fig 5B ) , in spite of a higher mean level of GFP expression. This finding suggests that functional endostatin was required for the growth -inhibitory effect. Similarly, cells expressing endostatin alone showed no perturbation of their growth in vivo. Although expression of endostatin from these cells was lower than from the NXS2 -Endo-I-GFP cells, probably because they contained no selectable marker with which highly transduced cells could be selected, this result highlights the contribution of the anti -GFP immune effect.
Analysis of the immune response to endostatin / GFP -expressing NXS2 cells
To investigate the role of T cell ±mediated cytotoxicity in the inability of the NXS2 -Endo -I -GFP cells to grow in the immunocompetent A /J mice, standard cytotoxicity assays were performed. Spleens were harvested from A /J mice that had failed to develop tumors by 1 month following subcutaneous inoculation with NXS2 -Endo -I -GFP neuroblastoma cells. Following coculture of these splenocytes for 6 days with irradiated NXS2-Endo -I -GFP cells, these splenocytes showed significant killing not only of NXS2 -I -GFP cells but also the unmodified parental cell line, which does not express GFP (Fig 6) . These data suggest that`c rosspriming'' of cytotoxic T cells (CTL ) for a tumorassociated antigen expressed by the unmodified tumor cell line had occurred. This killing was blocked nearly completely by the addition of an anti -CD3 antibody.
Splenocytes harvested from mice that had been given unmodified or GFP -expressing NXS2 cells, and subsequently grew tumors, showed no killing of target cells following coculture with either of these tumor cell lines. The importance of T cell ± mediated antitumor activity in vivo was confirmed by depleting mice of either CD4 + or CD8 + cells prior to tumor cell inoculation. Depletion of either of these T cell subpopulations permitted growth of NXS2 -Endo-I-GFP cells in 100% of the mice (Fig 7 ) .
One hallmark of immune -mediated tumor growth failure is the resistance of a subsequent tumor challenge. Therefore, 10 A /J mice in whom a tumor had failed to grow following initial inoculation with NXS2 -Endo-I-GFP cells were rechallenged with tumor cells in the opposite flank 1 month later. Half of the mice received unmodified NXS2 cells, whereas the other half received cells expressing GFP alone. None of the 10 mice subsequently went on to develop a tumor during a follow -up period of at least 2 months. These results further support the hypothesis that immune reactivity was contributing to the prevention of growth of the NXS2 -Endo-I-GFP cells in the syngeneic, immunocompetent A /J mice.
DISCUSSION
Endostatin has been shown to be among the most potent naturally occurring inhibitors of tumor-induced neovascularization and tumor growth. 7 Administration of recombinant protein to mice has caused regression of large primary tumors and prevented the spread of metastatic disease. 7, 10, 30 Problems have arisen, however, in the production of an active form of endostatin, particularly when attempting to manufacture the large quantities of recombinant protein required for clinical trials. One way to circumvent the nuances of protein production is to have the protein generated in situ by the host's own cells. This can be done through a gene therapy approach in which an expression cassette for endostatin is introduced into host target cells from which protein can be generated. Yoon et al 31 have demonstrated the efficacy of this strategy in which tumor cells themselves were modified to express this angiogenesis inhibitor. This approach was shown to result in the significant reduction of tumor-induced neovascularization and consequent restriction of in vivo tumor growth ( 73± 91% at 3 weeks ). The reduction of endostatin gene -modified tumor cell growth in immunodeficient mice was more modest in our tumor model ( 25% at 4 weeks ).
Although the most direct way to ensure that endostatin is expressed at all tumor sites is to modify the tumor cells themselves, this approach is ultimately not a practical one for patients who present with metastatic disease. Therefore, gene therapy approaches have also been tested in which therapeutic systemic levels of endostatin were achieved. This strategy has had some success ( 40± 70% tumor volume reduction ) , 32 ± 34 but in no instance was tumor growth completely prevented. In addition, the approaches have used either naked DNA or adenoviral vectors as delivery vehicles that generate only transient expression of endostatin. Because antiangiogenic therapy may only be cytostatic, long -term expression of this inhibitor is likely to be required for sustained anticancer efficacy. Although there are delivery systems that can direct long -term transgene expression, concerns exist regarding chronic angiogenesis inhibition because angiogenesis is a fundamental part of many normal, physiologic processes, such as reproduction and wound healing.
We have found an alternate approach in which the cytostatic effects of local angiogenesis inhibition were combined with the cytotoxic effects of an immune -mediated anticancer strategy. It has been reported recently that the commonly used marker protein, GFP, can be immunogenic when expressed by tumor cells in murine tumor models. Stripecke et al 18 found that nearly all immunocompetent, syngeneic mice challenged with certain GFP gene-modified leukemia and lymphoma cell lines rejected the tumor cells through a T cell ±mediated immune response. Although our results differed somewhat from these reports in that the GFP -expressing NXS2 cells were not rejected, we did observe a slightly decreased growth rate for these modified cells compared to unmodified NXS2 cells in immunocompetent, syngeneic A / J mice. This difference was not statistically significant, however, and no anti -GFP CTLs could be detected in mice challenged with the GFPexpressing cells. It is unclear why, in our study, the GFPexpressing tumor cells were still poorly immunogenic. Perhaps, the degree of anti -GFP response is strain -or tumor-related, or perhaps the level of GFP expression in our experiments was lower than that which generated significant anti -GFP immunity in the other studies. Nevertheless, even in our study, it is likely that the GFP -expressing tumor cells had a slightly increased immunogenicity given that the in vivo growth difference between the unmodified and GFPexpressing tumor cells in the syngeneic, immunocompetent A / J mice was completely eliminated when the cells were grown in immunodeficient C.B -17 SCID mice.
When endostatin was expressed together with GFP, however, a strong immune response was elicited. This was not due to greater GFP expression in these cells as the amount of GFP expression in the NXS2 -Endo -I -GFP, NXS2-Endo (P ) -I -GFP, and NXS2 -I -GFP cells was approximately the same. The cytotoxicity assays performed on splenocytes from mice that had failed to grow NXS2 -Endo-I-GFP tumors confirmed the presence of activated cytotoxic T lymphocytes. These CTLs were able to kill not only GFP -expressing tumor cell targets but also unmodified, parental cells in vitro. This finding suggests that crosspriming of the immune system to an antigenic determinant inherent to the tumor cells had occurred. That this was mediated, at least in part, by a classic T cell response was confirmed in vitro by blocking the cytotoxicity with a T cell ± neutralizing antibody and in vivo by depleting mice of CD4 and CD8 cells. In addition, the T cell ±mediated response provided lasting immunity; mice that had rejected an original challenge with NXS2 -Endo-I-GFP cells were protected from a subsequent challenge from both GFP -expressing NXS2 cells and unmodified NXS2 cells.
Thus, although neither autocrine expression of endostatin nor GFP alone resulted in long -term tumor suppression, a strong synergistic effect was observed when the angiogenesis inhibitor and immunogen were expressed in combination. The majority of immunocompetent A / J mice failed to grow tumors when inoculated with NXS2 -Endo-I-GFP cells and were protected from a subsequent tumor cell challenge. The mechanism for this synergy is uncertain. It may be that the contribution of endostatin is through its antiangiogenic effect on tumor neovasculature such that tumor growth is slowed sufficiently to permit a more effective immune response. Alternatively, endostatin may have some other mode of action that more directly affects immune effector cells. It is unlikely that this synergy is due to an immune response against endostatin as the endostatin used in this study is a normally expressed murine protein.
Additionally, NXS2 cells modified to express endostatin without GFP were not rejected by immunocompetent A /J mice. It is clear, however, that functional endostatin is required to achieve this synergistic effect. When a nonfunctional, mutant endostatin was expressed by the NXS2 cells, the growth of these tumor cells was unperturbed even though these cells had a higher mean expression of GFP than either the NXS2 cells expressing functional endostatin plus GFP or GFP alone. Further work is ongoing in an attempt to gain a better understanding of the mechanism of this synergy between the antiangiogenic activity of endostatin and the immunogenicity of GFP.
Synergy between treatment modalities that act through different mechanisms has often been observed and exploited in anticancer strategies. Specifically, synergy between angiogenesis inhibition and other approaches such as conventional chemotherapy, radiation therapy, and immunotherapy has been shown recently to be effective. This often provides the added benefit of permitting the use of lower doses of each agent to achieve antitumor efficacy. These lower doses are often far below the levels at which undesirable side effects of each individual modality might be observed. This synergy between angiogenesis inhibition and immunotherapy may be exploitable in anticancer vaccine strategies that currently appear to be efficacious only in settings of minimal residual disease.
